Immunoexpression of interleukin-1β in pancreatic islets of NOD mice during cyclophosphamide-accelerated diabetes: Co-localization in macrophages and endocrine cells and its attenuation with oral nicotinamide

Histochemical Journal

Volumn 33, Issue 6, 2001, Pages 317-327

  Reddy, S ^a   Young, M ^a   Ginn, S ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOKINE; INSULIN; INTERLEUKIN 1BETA; NICOTINAMIDE; NITRIC OXIDE SYNTHASE; SOMATOSTATIN; IMMUNOLOGICAL ADJUVANT; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DIABETES MELLITUS; DIABETOGENESIS; ENDOCRINE CELL; FEMALE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MOUSE; NONHUMAN; PANCREAS ISLET; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; ANIMAL; BIOSYNTHESIS; DRUG EFFECT; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; IATROGENIC DISEASE; METABOLISM; MOUSE STRAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PATHOLOGY;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ANIMAL; CYCLOPHOSPHAMIDE; DIABETES MELLITUS, NON-INSULIN-DEPENDENT; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; INTERLEUKIN-1; ISLETS OF LANGERHANS; MACROPHAGES; MICE; MICE, INBRED NOD; MICROSCOPY, CONFOCAL; NIACINAMIDE; NITRIC-OXIDE SYNTHASE; SUPPORT, NON-U.S. GOV'T;

EID: 0034746991     PISSN: 00182214     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012422821187     Document Type: Article

References (71)

1. Nicotinamide prevents interleukin-1 effects on accumulated insulin release and nitric oxide production in rat islets of Langerhans
2. Protection from nicotinamide inhibition of interleukin-1β-induced RIN cell nitric oxide formation is associated with induction of MnSOD enzyme activity
3. IL-1 produced and released endogenously within human islets inhibits β cell function
4. Potential role of resident islet macrophage activation in the initiation of autoimmune diabetes
5. Insulin-dependent diabetes mellitus as an autoimmune disease
6. Cytotoxicity of human pI interleukin-1 for pancreatic islets of Langerhans
7. In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis
8. Treatment with neutralising antibodies specific for IL-1β prevents cyclophosphamide-induced diabetes in non-obese diabetic mice
9. Evidence for IL-6 production by and effects on the pancreatic β-cell
10. TNF-β and IFN-γ potentiates the deleterious effects of IL-1β on mouse pancreatic islets mainly via generation of nitric oxide
11. Nicotinamide and dexamethasone inhibit interleukin-1-induced nitric oxide production by RINm5F cells without decreasing messenger ribonucleic acid expression for nitric oxide synthase
12. Interleukin-1 and interleukin-1 antagonism
13. Type 1 diabetes mellitus. A chronic autoimmune disease
14. Interleukin-1β induces the expression of an isoform of nitric oxide synthase in insulin-producing cells, which is similar to that observed in activated macrophages
15. Cytokines suppress human islet function irrespective of their effects on nitric oxide generation
16. Prevention or delay of type 1 (insulin-dependent) diabetes mellitus in children using nicotinamide
17. Immunoreactive α-interferon in insulin-secreting β cells in type 1 diabetes mellitus
18. The histopathology of the pancreas in type 1 (insulin-dependent) diabetes mellitus: A 25-year review of deaths in patients under 20 years of age in the United Kingdom
19. Insulitis in type 1 (insulin-dependent) diabetes mellitus in man-macrophages, lymphocytes, and interferon-γ containing cells
20. Inhibitory effect of nicotinamide on in vitro and in vivo production of tumour necrosis factor-α
21. Insulin-secreting β-cells possess specific receptors for interleukin-1β
22. Suppression of insulitis in non-obese diabetic (NOD) mice by oral insulin administration is associated with selective expression of interleukin-4 and -10, transforming growth factor-β, and prostaglandin-E
23. Inhibitors of poly(ADP-ribose) polymerase suppress lipopolysaccharide-induced nitrite formation in macrophages
24. Induction of nitric oxide synthase in L929 cells by tumour necrosis factor-α is prevented by inhibitors of poly(ADP-ribose) polymerase
25. Interleukin-1β modulates the acute release of growth hormone-releasing hormone and somatostatin from rat hypothalamus in vitro, whereas tumor necrosis factor and interleukin-6 have no effect
26. Interferon expression in the pancreases of patients with type I diabetes
27. Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes patients
28. Prevention of diabetes in non-obese diabetic mice by tumour necrosis factor (TNF). Similarities between TNF-α and interleukin
29. Localization and characterization of interleukin-1 receptors in the islets of Langerhans from control and non-obese diabetic mice
30. Characterization of pancreatic T lymphocytes associated with beta cell destruction in the non-obese diabetic (NOD) mouse
31. Essential contribution of macrophages to islet cell destruction in vivo and in vitro
32. Nicotinamide inhibits enhanced in vitro production of interleukin-12 and tumour necrosis factor-α in peripheral whole blood of people at high risk of developing Type 1 diabetes and people with newly diagnosed Type 1 diabetes
33. Interleukin-1β-induced nitric oxide synthase expression by rat pancreatic β-cells: Evidence for the involvement of nuclear factor κB in the signalling mechanism
34. Immunoreactive interleukin-1β localization in the rat forebrain
35. Human islets of Langerhans express Fas ligand and undergo apotosis in response to interleukin-1β and Fas ligation
36. The role of interleukin-1 in the pathogenesis of IDDM
37. Cytokines cause functional and structural damage to isolated islets of Langerhans
38. Cytokines as immune effector molecules in autoimmune endocrine diseases with special reference to insulin-dependent diabetes mellitus
39. Cytokines and free radicals as effector molecules in the destruction of pancreatic beta cells
40. Fas and Fas ligand expression in inflamed islets in pancreas sections of patients with recent-onset Type I diabetes mellitus
41. Th1 and Th2 cells: Different patterns of lymphokine secretion lead to different functional properties
42. Protection from experimental autoimmune diabetes in the non-obese diabetic mouse with soluble interleukin-1 receptor
43. Resistance to endotoxic shock as a consequence of defective NF-κB activation in poly (ADP-ribose) polymerase-1 deficient mice
44. Monokine-producing cells predominate in the recruitment phase of NOD insulitis while cells producing Th1-type cytokines characterize the effector phase
45. Nicotinamide: Biological actions and therapeutic potential in diabetes prevention
46. Prevention of insulin-dependent diabetes mellitus
47. Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM: Therapeutic intervention by immunostimulation?
48. An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus
49. Human pancreatic islet β destruction by cytokines is independent of nitric oxide production
50. IL-4 reverses T-cell proliferative unresponsiveness and prevents the onset of diabetes in NOD mice
51. Early nicotinamide treatment in the NOD mouse: Effects on diabetes and insulitis suppression and autoantibody levels
52. Long-term effects of nicotinamide induced inhibition of poly(adenosine diphosphate-ribose) polymerase activity in rat pancreatic islets exposed to interleukin-1β
53. Immunohistochemical analyses of pancreatic macrophages and CD4 and CD8 T cell subsets prior to and following diabetes in the NOD mouse
54. An immunohistochemical study of macrophage influx and the co-localization of inducible nitric oxide synthase in the pancreas of non-obese (NOD) mice during disease acceleration with cyclophosphamide
55. Temporal relationship between immune cell influx and the expression of inducible nitric oxide synthase, interleukin-4 and interferon-γ in pancreatic islets of NOD mice following adoptive transfer of diabetic spleen cells
56. Dual-label immunohistochemical study of interleukin-4- and interferon-γ-expressing cells within the pancreas of the NOD mouse during disease acceleration with cyclophosphamide
57. Prevention of cyclophosphamide-induced accelerated diabetes in the NOD mouse by nicotinamide or a soy protein-based infant formula
58. Inhibitory effects of interleukin-1 on insulin secretion, insulin biosynthesis, and metabolism of isolated rat pancreatic rat islets
59. Pancreas in recent onset insulin-dependent diabetes mellitus. Changes in HLA, adhesion molecules and autoantigens, restricted T cell receptor Vβ usage, and cytokine profile
60. Inhibition of insulin secretion by interleukin-1β and tumour necrosis factor-α via an L-argininedependent nitric oxide generating mechanism
61. Nitric oxide primes pancreatic β cells for Fas-mediated destruction in insulin-dependent diabetes mellitus
62. Expression of apoptosis-inducing CD95 (Fas/Apo-1) on human β-cells sorted by flow-cytometry and cultured in vitro
63. β-cell destruction in NOD mice correlates with Fas(CD95) expression on β-cells and proinflammatory cytokine expression in islets
64. Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthatase
65. Comparison of mRNA contents of intedeukin-1β and nitric oxide synthase in pancreatic islets isolated from female and male nonobese diabetic mice
66. Preventive and therapeutic effects of large dose nicotinamide injections on diabetes associated with insulitis: An observation in non-obese diabetic (NOD) mice
67. Pancreatic β-cell-selective production of tumour necrosis factor-α induced by interleukin-1
68. Mouse islet cell lysis mediated by interleukin-1-induced Fas
69. Dominant TCR α-chain clonotypes and interferon-γ are expressed in the pancreas of patients with recent-onset insulin-dependent diabetes mellitus
70. Amelioration of diabetes mellitus in partially depancreatized rats by poly(ADP-ribose) synthetase inhibitors. Evidence of islet B-cell regeneration
71. Genetic disruption of poly (ADP-ribose) synthetase inhibits the expression of P-selectin and intercellular adhesion molecule-1 in myocardial ischemia/reperfusion injury